Short Interest in Cerus Corporation (NASDAQ:CERS) Declines By 29.2%

Key Points

• Short interest in Cerus Corporation has declined significantly, dropping by 29.2% to 6,900,000 shares as of August 31, indicating a decreasing bearish sentiment towards the stock.
• Cerus reported a $60.1 million in revenue for the last quarter, surpassing analyst expectations of $51.8 million, despite EPS of ($0.03) that missed the consensus estimate.
• Institutional investors currently own 78.37% of Cerus shares, with notable increases in holdings from companies like Wasatch Advisors and Millennium Management.

Cerus Corporation (NASDAQ:CERS - Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 6,900,000 shares, a drop of 29.2% from the August 15th total of 9,740,000 shares. Currently, 3.8% of the company's shares are short sold. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is currently 6.3 days. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is currently 6.3 days. Currently, 3.8% of the company's shares are short sold.

Cerus Stock Performance

Shares of CERS stock opened at $1.20 on Tuesday. The company has a market cap of $230.04 million, a price-to-earnings ratio of -12.00 and a beta of 1.63. Cerus has a 52 week low of $1.12 and a 52 week high of $2.24. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The firm has a 50 day moving average of $1.32 and a 200-day moving average of $1.35.

Cerus (NASDAQ:CERS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $60.10 million for the quarter, compared to analyst estimates of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Cerus will post -0.08 earnings per share for the current year.

Hedge Funds Weigh In On Cerus

A number of large investors have recently modified their holdings of the company. Wasatch Advisors LP lifted its holdings in shares of Cerus by 2.6% in the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company's stock worth $12,033,000 after purchasing an additional 213,917 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock worth $4,479,000 after purchasing an additional 344,395 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock worth $3,710,000 after purchasing an additional 733,683 shares in the last quarter. Ieq Capital LLC lifted its holdings in shares of Cerus by 4.2% in the 2nd quarter. Ieq Capital LLC now owns 2,418,263 shares of the biotechnology company's stock worth $3,410,000 after purchasing an additional 97,467 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Cerus by 6.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock worth $2,466,000 after purchasing an additional 107,771 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.